General News

NHS Trust: Patients Harmed by Unnecessary Chemotherapy

A Royal College of Physicians report has found that patients at University Hospitals Coventry and Warwickshire NHS trust suffered severe harm due to years of unnecessary chemotherapy. The investigation into treatment provided by a retired oncologist suggests that many individuals received long-term cycles of drugs without evidence of benefit. Legal representatives are now calling for an independent public inquiry into the matter.

Unsatisfactory Care Identified

A report from the Royal College of Physicians has revealed that patients at University Hospitals Coventry and Warwickshire NHS trust were harmed by receiving unnecessary chemotherapy. The investigation focused on the care provided to brain tumour patients by a retired clinical oncologist, Ian Brown. The findings suggest that the treatment protocols used were often inappropriate for the conditions being managed.

According to the Royal College of Physicians, the investigation examined 20 specific cases of care. Out of these, 15 cases were found to have received unsatisfactory care, while a further five cases were identified as requiring improvement. This assessment highlights failings in the clinical management of patients during the period in question.

The report states that patients were given long-term cycles of the drug temozolomide without any evidence of benefit. This medication is typically used for six months following radiotherapy for brain tumours such as astrocytoma and glioblastoma. The findings suggest that the extended use of the drug was not supported by clinical evidence for these patients.

The Royal College of Physicians also noted concerns regarding the way consent was documented or obtained in all 20 cases examined. This lack of clarity regarding patient agreement adds to the concerns raised about the standard of care provided. The investigation was commissioned after colleagues raised issues during the handover of patients following the retirement of the oncologist in December 2023.

Severe Harm to Patients

The impact on those receiving treatment has been significant, with the Royal College of Physicians categorising the level of harm experienced. The report concludes that six patients suffered severe harm, while five others experienced moderate harm. An additional eight patients were found to have suffered low levels of harm from the treatment they received.

Specific instances of medical error were highlighted within the investigation. One patient was incorrectly diagnosed with a deadly glioblastoma but was actually suffering from a low-grade pilocytic astrocytoma, which did not require chemotherapy. Another individual received treatment for 10 years for a condition that was later identified as tumefactive demyelination.

The risks associated with the medication were also evidenced in the findings. One patient who received the drug for more than 10 years developed acute myeloid leukaemia, which the Royal College of Physicians noted is a known risk of temozolomide. This highlights the potential physical toll of prolonged chemotherapy cycles on vulnerable individuals.

The emotional impact on patients has also been documented through their experiences. Becky Jones, a patient, said: "For years, I questioned why I was still being given chemotherapy when my scans were stable, but I was repeatedly told that without it I would die".

Failings in Trust Oversight

The investigation has raised serious questions about the internal monitoring systems at the University Hospitals Coventry and Warwickshire NHS trust. The Royal College of Physicians described the oversight systems at the trust as ineffective. This lack of scrutiny meant there were missed opportunities to challenge care that was deemed unsafe.

Financial implications of the prescribing patterns have also been noted. The Independent reported that the trust spent over £3.6m on temozolomide between 2007 and 2023. This figure is reported to be more than 10 times higher than the spending seen at comparable hospitals.

The scale of the issue may extend beyond the 20 cases specifically examined by the Royal College of Physicians. The report notes that the total number of affected patients might be higher, particularly if those who have since died are included in the data. This remains an open question for the health service.

The trust is now facing pressure to account for these systemic failures. With the oversight mechanisms failing to catch the prolonged use of chemotherapy, the investigation suggests a breakdown in the standard safety checks required for oncology patients.

Legal and Police Involvement

Legal action is being prepared as a result of the findings. The law firm Brabners is currently representing 40 patients affected by the situation. Becky Addison, a representative from Brabners, is part of the legal effort to seek accountability for those harmed by the treatment.

The legal firm is also calling for the establishment of an independent public inquiry. This move follows the revelation of the scale of unnecessary treatment and the harm caused to patients. Such an inquiry would look more broadly at the clinical decisions and the lack of oversight at the trust.

There have also been referrals to law enforcement regarding the matter. According to Brabners, cases have been referred to the police, although no action has been taken by authorities at this stage. This adds a criminal dimension to the ongoing investigation into the retired oncologist's practice.

The scrutiny continues as the legal and regulatory implications of the report are assessed. The focus remains on whether the failures were purely clinical or if they represent a wider breakdown in the governance of the NHS trust.

Regulatory and Safety Steps

The trust is taking steps to address the findings through various reviews. It has extended its historical review process back to 2005 to understand the full extent of the prescribing. This is intended to identify any other patients who may have been impacted by the clinical decisions made during that period.

Further actions are being taken regarding specific staff members. The trust has submitted a formal report to the Nursing and Midwifery Council concerning Ian Edwards, a clinical nurse specialist. This move is part of the wider response to the clinical failings identified in the report.

Regarding the patients who are still living, the trust has been advised on specific safety measures. The trust should ensure all living patients who have undergone more than 12 rounds of temozolomide have their cases independently reviewed. This aims to prevent further unnecessary harm to those currently under care.

The trust has also begun talking to the regional director of patient safety for NHS England about how to review deceased patients. The trust needs to decide if such a review is appropriate in consultation with the DHSC or NHS England.